-
1.
公开(公告)号:US09233142B2
公开(公告)日:2016-01-12
申请号:US14292940
申请日:2014-06-02
申请人: NATIONAL HOSPITAL ORGANIZATION, KINKI-CHUO CHEST MEDICAL CENTER, partial interest , AZBIO CORPORATION, partial interest , Masaji Okada, partial interest , Yasushi Takamori, partial interest
发明人: Masaji Okada , Yasushi Takamori , Kazuyuki Ogawa , Kinya Nagata
CPC分类号: A61K38/20 , A61K38/164 , A61K38/1709 , A61K38/1729 , A61K38/204 , A61K38/208 , A61K39/04 , A61K2300/00
摘要: (Problems) To provide a therapeutic agent for infections comprising granulysin as an active ingredient which has little side effect and no cytotoxicity and to which bacteria can hardly acquire resistance, and a treatment method using the same.(Means for Solving Problems) The present invention provides a therapeutic agent for infections comprising as active ingredient: 15K granulysin, a combination of 15K granulysin and 15K granulysin in vivo expression vector, a combination of 15K granulysin and at least one interleukin selected from IL-6, IL-23 or IL-27, a combination of 15K granulysin in vivo expression vector and at least one interleukin selected from IL-6, IL-23 or IL-27, or a combination of 15K granulysin in vivo expression vector and HSP65DNA and IL-12DNA in vivo expression vector, which enhances killing effects on bacteria and has less side effect, and to which bacteria can hardly acquire resistance, and a treatment method using the same.
摘要翻译: (问题)为了提供包含颗粒溶素作为活性成分的感染治疗剂,其副作用小,无细胞毒性,细菌几乎不能获得抗性,以及使用该治疗剂的治疗方法。 (解决问题的手段)本发明提供一种感染治疗剂,其包含15K颗粒溶素,15K颗粒溶素和15K颗粒溶素在体内表达载体的组合,15K颗粒溶素与至少一种选自IL- 6,IL-23或IL-27,15K颗粒溶素在体内表达载体和选自IL-6,IL-23或IL-27中的至少一种白介素或15K颗粒溶素的体内表达载体和HSP65DNA的组合的组合 和IL-12DNA体内表达载体,其对细菌的杀伤作用增强,副作用较小,细菌几乎不能获得抗性,以及使用其的处理方法。